首页> 外文期刊>The Internet Journal of Third World Medicine >Fistuloclysis: Cost Effective Nutrition for Patients with Enterocutaneous Fistulae
【24h】

Fistuloclysis: Cost Effective Nutrition for Patients with Enterocutaneous Fistulae

机译:瘘管切开术:肠胃瘘患者的经济有效营养

获取原文
           

摘要

This manuscript highlights the financial benefits derived from fistuloclysis when used for nutrient delivery in patients with enterocutaneous fistulae. Introduction Enterocutaneous Fistulae (ECF) may be challenging to manage because large volume fistula losses may result in severe dehydration, electrolyte imbalances, malnutrition and sepsis (1). Recognizing and correcting these complications are prerequisites to successful ECF management.Nutritional support is especially important because malnutrition is an independent predictor of post-operative morbidity and mortality regardless of age, cardiorespiratory function or operation type (2,3). Central vein parenteral nutrition (PN) is used liberally while awaiting spontaneous ECF closure or optimizing patients for operation (1,4). But it carries the risk of electrolyte derangements, metabolic disturbances, catheter related complications and sepsis (5,6). Moreover, the cost of prolonged PN may limit its availability in Developing Countries.Fistuloclysis is a viable alternative in select patients, thereby avoiding PN and its attendant complications (4,7). The technique was initially described by Teubner et al who delivered enteral feeds directly into a balloon retention gastrostomy tube passed 5cm into the distal limb of an ECF (4). In their report, fistuloclysis successfully replaced PN in 11 of 12 patients within 28 days of commencement (4).
机译:该手稿着重指出了纤溶技术在肠胃瘘患者中用于营养输送时所带来的经济利益。简介肠内瘘(ECF)的管理可能具有挑战性,因为大量的瘘管损失可能导致严重的脱水,电解质失衡,营养不良和败血症(1)。认识和纠正这些并发症是成功进行ECF治疗的前提条件。营养支持尤其重要,因为营养不良是术后发病率和死亡率的独立预测因子,与年龄,心肺功能或手术类型无关(2,3)。在等待自发ECF闭合或优化患者手术时,可广泛使用中央静脉肠胃外营养(PN)(1,4)。但是它存在着电解质紊乱,代谢紊乱,导管相关并发症和败血症的风险(5,6)。此外,延长PN的成本可能会限制其在发展中国家的可用性.Fistuloclysis是某些患者的可行选择,从而避免了PN及其伴随的并发症(4,7)。 Teubner等人最初描述了该技术,他们将肠内饲料直接送入气囊保留胃造口术管,该管通过5cm进入ECF的远端肢体(4)。在他们的报告中,纤溶治疗在开始的28天内成功替代了12例患者中的11例PN(4)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号